When to Stop Ketorolac Before Surgery
Ketorolac should be discontinued 24-48 hours before most surgical procedures, with consideration for stopping 3-5 days prior to high-bleeding-risk surgeries such as intracranial or spinal procedures.
Evidence-Based Timing
The provided guidelines do not contain specific recommendations for ketorolac discontinuation timing. However, the FDA drug label provides critical safety information that informs perioperative management 1.
Key Pharmacologic Considerations
Ketorolac causes irreversible platelet inhibition similar to other NSAIDs, with platelet function restoration occurring at approximately 10-15% per day as new platelets are generated 2. The drug and its metabolites are eliminated primarily by the kidneys 1.
Recommended Discontinuation Timeline
For standard surgical procedures:
- Stop ketorolac 24-48 hours before surgery to allow partial restoration of platelet function
- This timing balances the drug's elimination with the gradual return of hemostatic capacity
For high-bleeding-risk procedures (intracranial surgery, spinal surgery, procedures where hemostasis is critical):
- Stop ketorolac 3-5 days before surgery to allow more complete platelet function recovery
- This extended timeline is particularly important given the FDA warning that "peri-operative use of ketorolac should be avoided...when hemostasis is critical" 1
Critical Risk Factors Requiring Extended Discontinuation
Stop ketorolac 5 days before surgery in patients with:
- Concurrent anticoagulant therapy (warfarin, heparin, DOACs)
- Coagulation disorders
- Renal impairment (reduced drug clearance prolongs effects) 1
- Concurrent antiplatelet therapy
- History of bleeding complications
Clinical Context from Related Guidelines
While the ACCP guidelines address aspirin and P2Y12 inhibitors rather than ketorolac specifically, they provide relevant context: aspirin is typically stopped ≤7 days before surgery when interruption is needed 3, and clopidogrel is stopped 5 days before CABG 4. Given ketorolac's similar mechanism of irreversible platelet inhibition but shorter duration of action, the 24-48 hour window for standard procedures and 3-5 days for high-risk procedures represents a clinically prudent approach.
Common Pitfalls to Avoid
- Do not continue ketorolac perioperatively in patients undergoing procedures where even minor bleeding could have catastrophic consequences (neurosurgery, ophthalmologic procedures in closed spaces)
- Do not assume rapid reversal - unlike some anticoagulants, there is no reversal agent for ketorolac's antiplatelet effects
- Do not overlook renal function - patients with impaired renal function require longer discontinuation periods due to reduced drug clearance 1
- Avoid concurrent hemostasis-affecting medications - the FDA label explicitly warns that concurrent use with anticoagulants "should be undertaken only extremely cautiously" 1
Postoperative Resumption
The FDA label reports postoperative hematomas and wound bleeding with perioperative ketorolac use 1. Resume ketorolac only after:
- Adequate surgical hemostasis is confirmed
- At least 24-48 hours post-procedure for standard surgeries
- Longer delays for high-bleeding-risk procedures
- Platelet count is adequate (>50,000/μL if measured)